Clinical Trials · NCT02225366
Intratumoral Injections of LL37 for Melanoma
- Phase
- Phase 1/Phase 2
- Recruitment status
- Completed
- Sponsor
- M.D. Anderson Cancer Center
- Enrollment
- 4
- Start date
- Jul 2015
- Locations
- 1 site, United States
- Primary endpoint
- Number of Participants With Optimal Biological Dose (OBD) of LL37 Based Upon Toxicity